🇺🇸 FDA
Pipeline program

Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

RM-718-001

Phase 2 small_molecule active

Quick answer

Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) for Hypothalamic Obesity is a Phase 2 program (small_molecule) at RHYTHM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
RHYTHM PHARMACEUTICALS, INC.
Indication
Hypothalamic Obesity
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials